Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02037022 · ClinicalTrials.gov registry record · NA
Pivotal Response Treatment Package for Young Children With Autism
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
NCT02037022: Completed NA study, sponsored by Stanford University.
NCT02037022 is a NA study that has completed, run by Stanford University. The registered enrollment target is 48 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02037022, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a research study examining the effectiveness of a pivotal response treatment package (PRT-P) in targeting language skills in young children with autism.
Interventions
- BEHAVIORAL Pivotal Response Treatment Package (PRT-P)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-12-04 |
| Est. Completion | 2017-07-28 |
| Phase | NA |
What the finished NCT02037022 record still lists
NCT02037022 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Pivotal Response Treatment Package (PRT-P) is the first listed.
NCT02037022 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02037022 about?
NCT02037022 is a clinical study titled "Pivotal Response Treatment Package for Young Children With Autism". This is a research study examining the effectiveness of a pivotal response treatment package (PRT-P) in targeting language skills in young children with autism.
What is the current status of trial NCT02037022?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2013-12-04. Estimated completion is 2017-07-28.
What interventions are being tested in trial NCT02037022?
The interventions under investigation include: Pivotal Response Treatment Package (PRT-P) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02037022?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02037022's enrollment target sits among peer trials
48 1381st of 2000 higher than 601 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI